Valuation: LENZ Therapeutics, Inc.

Market Cap 179M 158M 147M 135M 253M 17.18B 259M 1.74B 682M 8.5B 673M 659M 29.39B P/E 2026 *
-1.27x
P/E 2027 * -1.67x
Enterprise Value 179M 158M 147M 135M 253M 17.18B 259M 1.74B 682M 8.5B 673M 659M 29.39B EV / Sales 2026 *
9.45x
EV / Sales 2027 * 2.84x
Free-Float
97.35%
Yield 2026 *
-
Yield 2027 * -
1 day-2.72%
1 week+7.12%
Current month+0.70%
1 month-0.69%
3 months-36.80%
6 months-67.83%
Current year-64.25%
1 week 5.03
Extreme 5.03
6.14
1 month 4.68
Extreme 4.68
6.21
Current year 4.68
Extreme 4.68
21.8
1 year 4.68
Extreme 4.68
50.4
3 years 4.68
Extreme 4.68
50.4
5 years 4.68
Extreme 4.68
50.4
10 years 4.68
Extreme 4.68
50.4
Date Insider Type Main position Quantity % Market Cap.
6/15/26 Free

Founder

22,100 0.0705%
6/15/26 Free

Director

22,100 0.0705%
6/15/26 Free

Director

22,100 0.0705%
Change 5-day change 1-year change 3-year change Capi.($)
-2.72%+7.12%-81.94% - 184M
+0.47%+2.27%+50.78%+70.84% 55.01B
+2.83%+0.48%+28.18%+82.59% 54.24B
+0.54%+1.22%-16.62%-13.47% 23.38B
-0.97%-3.30%-1.79%+383.00% 22.57B
+2.07%+1.39%+17.20%-9.05% 20.19B
-2.15%-2.30%+27.27%-31.03% 17.86B
-2.14%-3.75%+26.23%+536.72% 15.5B
-3.14%-8.47%+165.37%+292.18% 14.2B
-2.09%+0.64%+49.78%+178.74% 14.2B
Average -0.73%+0.90%+26.45%+165.61% 23.73B
Weighted average by Cap. +0.28%-0.10%+34.44%+130.62%

Financials

2026 *2027 *
Net sales 18.98M 16.68M 15.57M 14.29M 26.75M 1.82B 27.41M 185M 72.2M 900M 71.27M 69.72M 3.11B 63.18M 55.52M 51.82M 47.56M 89.02M 6.05B 91.22M 614M 240M 2.99B 237M 232M 10.35B
Net income -141M -124M -116M -106M -199M -13.54B -204M -1.37B -538M -6.7B -531M -519M -23.16B -111M -97.28M -90.81M -83.34M -156M -10.6B -160M -1.08B -421M -5.25B -416M -407M -18.14B
Net Debt - -
Logo LENZ Therapeutics, Inc.
LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
Employees
152
Date Price Change Volume
26-07-29 US$5.720 -2.72% 722,564
26-07-28 US$5.880 +3.16% 639,369
26-07-27 US$5.700 +4.01% 1,181,399
26-07-24 US$5.480 +8.51% 1,429,508
26-07-23 US$5.050 -5.43% 613,457
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.720USD
Average target price
32.00USD
Spread / Average Target
+459.44%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LENZ Stock